auf anzeigen
id | online | Artikelnummer | Titel | Sub titel | Beschreibung | Beschreibung kurz | |||||||||||||||||||||||||||||||
1 | Y | 1000000 | Electrolyte infusion solution 153 m. Glucose 5, 500 ml glass bottle | Total cations/anions 153 mval/l each, D-glucose 5 % |
For use in adults infusion solution for intravenous use Application / Use Electrolyte infusion solution 153 with glucose 5 is an infusion solution administered into a vein. This solution replaces fluid, salts and sugars lost from the circulatory system. It can also be used in cases where your blood is slightly acidic. The solution can also be used as a carrier solution for other salts and medicines. Active ingredients / components 1 l infusion solution contains the following active ingredients:
(A mmol/l: Na+ 140, K+ 5, Ca2+ 2.5, Mg2+ 1.5, Cl- 103, acetate ions 50) The other ingredients are water for injection and hydrochloric acid 36 %. Sterile and pyrogen-free. pH: 5.0 - 6.0 Energy content: 840 kJ/l (200 kcal/l) Theoretical osmolarity: 581 mOsm/l Titration acidity: < 3 mmol/l to pH 7.4 Electrolyte infusion solution 153 with glucose 5 is available in glass bottles in the following package sizes: 1 x 500 ml 10 x 500 ml
|
||||||||||||||||||||||||||||||||
2 | Y | 1000001 | Electrolyte - IL 148 with glucose 1 Paed 250 ml (glass) | The first optimized and balanced pediatric solution for perioperative infusion therapy |
E 148 G1 PÄD prevents derailments:
Active ingredient Sodium chloride 6.429 g, potassium chloride 0.298 g, calcium chloride dihydrate 0.147 g, magnesium chloride hexahydrate 0.203 g, sodium acetate trihydrate 4.082 g, glucose monohydrate 11.0 g For further information, please refer to the technical information. |
||||||||||||||||||||||||||||||||
3 | Y | 1000003 | Electrolyte infusion solution 75 m. Glucose 5, 500 ml glass bottle | Total cations/anions 75 mval/l each, D-glucose 5%, infusion solution for intravenous use |
Substitution of fluids and electrolytes with low percentage carbohydrate, especially in postoperative and post-traumatic infusion therapy, when the application of sodium-rich drugs is additional Carrier solution for compatible electrolyte concentrates and drugs Active ingredients / components
Other ingredients:
|
||||||||||||||||||||||||||||||||
4 | Y | 1000006 | CitraFleet - powder 2 pieces | Successful colon cleansing |
For bowel cleansing before any diagnostic examination that can be meaningfully performed only if the bowel is well cleansed, e.g. a colonoscopy or X-ray examination. CitraFleet is used in adults 18 years and older. Product information
Features
|
||||||||||||||||||||||||||||||||
5 | Y | 1000007 | CitraFleet - sachets of 100 pieces in a carton | Successful colon cleansing |
For bowel cleansing before any diagnostic examination that can be meaningfully performed only if the bowel is well cleansed, e.g. a colonoscopy or X-ray examination. CitraFleet is used in adults 18 years and older. Product information
Features
|
||||||||||||||||||||||||||||||||
8 | Y | 1000016 | Restoric Nephro Prae chocolate |
Without anticoagulant for the preparation of lightly concentrated platelet-rich plasma. Application wPRP - Acute:
wPRP – Chronic
Concentration / Yield
|
|||||||||||||||||||||||||||||||||
9 | Y | 1000017 | Restoric Nephro Intra D mixed carton | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
10 | Y | 1000018 | Restoric Nephro Intra D Chocolate | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
11 | Y | 1000019 | Restoric Nephro Intra D Biscuit & Capuccino | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
12 | Y | 1000020 | Restoric Nephro Intra D Strawberry | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
13 | Y | 1000021 | Restoric Nephro Intra D Vanilla | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
14 | Y | 1000022 | Restoric Nephro Intensive Vanilla | Drinking and tube feeds for dialysis patients |
The right tube feeding from the beginning facilitates intensive therapy and promotes long-term stability even in outpatient care. Intensive care in nephrology, cardiology and surgery. Due to its special composition, Restoric Nephro intensive contributes to metabolic stability, promotes convalescence and can thus lead to a shorter stay in the intensive care unit. The sip and tube feed nutrition is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intensiv should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician. In case of supplementary nutrition:
For exclusive nutrition: The energy requirement of dialysis patients is given as 30-35 kcal/kg target body weight. The table shows guideline values, but energy requirements may be significantly lower or higher than these values in individual cases and must always be adjusted to individual needs. Restoric nephro intensive can be taken as a drinkable food at any time. In the case of supplementary nutrition, the drinkable food should be taken as a snack. |
||||||||||||||||||||||||||||||||
15 | Y | 1000023 | Isot. NaCl solution 0.9% 250 ml, 30 pieces |
PropyBAG - Saline bags for use in dialysis centers and hospitals Advantages
The saline bags are available in four different sizes: 250 ml, 500 ml, 1000 ml and 2000 ml Areas of application Fluid and electrolyte substitution in hypochloremic alkalosis, chloride losses, short-term intravascular volume replacement, hypotonic dehydration, isotonic dehydration |
|||||||||||||||||||||||||||||||||
16 | Y | 1000024 | Isot. NaCl solution 0.9% 500ml, 20 pcs. |
PropyBAG - Saline bags for use in dialysis centers and hospitals Advantages
The saline bags are available in four different sizes: 250 ml, 500 ml, 1000 ml and 2000 ml Areas of application Fluid and electrolyte substitution in hypochloremic alkalosis, chloride losses, short-term intravascular volume replacement, hypotonic dehydration, isotonic dehydration |
|||||||||||||||||||||||||||||||||
17 | Y | 1000025 | Isot. NaCl solution 0.9% 1000ml, 10 pieces |
PropyBAG - Saline bags for use in dialysis centers and hospitals Advantages
The saline bags are available in four different sizes: 250 ml, 500 ml, 1000 ml and 2000 ml Areas of application Fluid and electrolyte substitution in hypochloremic alkalosis, chloride losses, short-term intravascular volume replacement, hypotonic dehydration, isotonic dehydration |
|||||||||||||||||||||||||||||||||
18 | Y | 1000026 | Isot. NaCl solution 0.9% 2000ml, 5 pieces |
PropyBAG - Saline bags for use in dialysis centers and hospitals Advantages
The saline bags are available in four different sizes: 250 ml, 500 ml, 1000 ml and 2000 ml Areas of application Fluid and electrolyte substitution in hypochloremic alkalosis, chloride losses, short-term intravascular volume replacement, hypotonic dehydration, isotonic dehydration |
|||||||||||||||||||||||||||||||||
20 | Y | 1000031 | Spherox 10-70 Spheroids/cm2 suspension for implantation |
What is Spherox? SPHEROX is the only EMA-approved ATMP for the treatment of cartilage damage. Spherox consists of so-called spheroids. A spheroid looks like a small bead of cartilage cells and cartilage material that come from your own body. The spheroids are implanted into the damaged cartilage area and immediately adhere to the damaged area. Keyfacts
Personalisierter Prozess Biopsy
Cultivation
Transplantation
|
|||||||||||||||||||||||||||||||||
21 | Y | 1000032 | Restornic Nephro Intra D Neutral | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
23 | Y | 1000035 | Restoric Nephro Intra D Cappucino | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
24 | Y | 1000036 | Restoric Nephro Intra D Biscuit | Drinking food for dialysis patients |
Restoric nephro intra D supports nutrition to meet requirements in the context of dietary management in the event of existing or impending malnutrition and food intake disorders. The drinkable food is specially adapted to the needs of patients with renal insufficiency requiring dialysis. How much restoric nephro intra D should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the physician.
In case of exclusive nutrition with restoric nephro intra D, the dosage must be further increased and adapted to the individual energy requirements of the patient. Restoric nephro intraD can be taken at any time. In case of supplementary nutrition, the sip feed should be taken as a snack. Properties
|
||||||||||||||||||||||||||||||||
25 | Y | 1000037 | Sodium chloride solution 1 molar 100ml | Electolyte concentrate |
For cental venous infusion after addition to infusion solutions Indications
Precautions for use
See also under warnings. Pregnancy or lactation There are no objections to use during pregnancy or lactation. Qualitative and quantitative composition 1 l infusion solution concentrate contains:
Active ingredient: Sodium chloride 58.44 g (≙mmol/ml: Na⁺1, CI- 1).
Other ingredient: Water for injections.
Sterile and pyrogen-free. Ph: 4.5-7.0 Theoretical osmolarity: 2 000 mOsm/l Titration acidity up to pH 7.4: <0.3 mmoI/I
Please refer to the Instructions for Use for more details. |
||||||||||||||||||||||||||||||||
26 | Y | 1000038 | Potassium chloride solution 1 molar 50ml |
for intravenous infusion after addition to infection solutions
Indications
Precautions for use
Mode of administration
See also warnings Pregnancy and lactation There are no objections to use during pregnancy and lactation when indicated. Qualitative and quantitative composition 1000 ml infusion solution concentrate contains: Active ingredient: Potassium chloride 74.56 g (≙mmol/ml: K⁺ 1, CI- 1). Other ingredient: Water for injections. Sterile and pyrogen-free. pH: 4.5 - 7.5 Theoretical osmolarity: 2000 mOsm/l
For more details, please refer to the instructions for use. |
|||||||||||||||||||||||||||||||||
27 | Y | 1000039 | Potassium chloride solution 1 molar 100 ml | Electrolyte concentrate |
for intravenous infusion after addition to infection solutions
Indications
Precautions for use
Mode of administration
See also warnings Pregnancy and lactation There are no objections to use during pregnancy and lactation when indicated. Qualitative and quantitative composition 1000 ml infusion solution concentrate contains: Active ingredient: Potassium chloride 74.56 g (≙mmol/ml: K⁺ 1, CI- 1). Other ingredient: Water for injections. Sterile and pyrogen-free. pH: 4.5 - 7.5 Theoretical osmolarity: 2000 mOsm/l
For more details, please refer to the instructions for use. |
||||||||||||||||||||||||||||||||
28 | Y | 1000040 | Restoric supportive S mixed carton |
Food for special medical purposes (balanced diet) for dietary management in cases of existing or threatened malnutrition as well as in cases of food intake disorders: high-protein, high-calorie, completely balanced drinkable food with dietary fiber. Properties restoric supportiv S Vegan supports dietary management in cases of existing or impending malnutrition as well as in cases of food intake disorders. The drinkable food is specially adapted to the needs of patients with malnutrition due to illness or age:
How much restoric supportiv S Vegan should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the doctor.
For exclusive nutrition, the dosage is to be calculated according to the individual energy requirement. restoric supportiv S Vegan should be taken as a snack. The intake of restoric supportiv S Vegan can take place at any time. In case of supplementary nutrition, the drinkable food should be taken as a snack. In this case, restoric supportiv S Vegan can be taken as a second breakfast, in the afternoon or before going to bed. It is recommended to drink the supplementary food one hour after a main meal rather than one hour before a larger meal. |
|||||||||||||||||||||||||||||||||
29 | Y | 1000041 | NUBAIN Solution for Injection 10mg/ml, 10 vials |
Active substance: nalbuphine hydrochloride What is Nubain and what is it used for? Nubain contains the active ingredient nalbuphine hydrochloride, which is a medicine that belongs to the group of opioid-type painkillers (analgesics). It is used for short-term treatment of moderate to severe pain. It may also be used to treat pain before or after surgery. Route of administration Intravenous, intramuscular, or subcutaneous use. Because intramuscular and subcutaneous use can be painful, intravenous use is preferred in children. What Nubain contains
1 ampoule of 2 ml contains 20 mg of nalbuphine hydrochloride.
Pharmaceutical entrepreneur and manufacturer Pharmaceutical entrepreneur Altamedics GmbH Josef-Lammerting-Allee 16 50933 Cologne Germany Manufacturer Laboratoire Renaudin Z.A. Errobi 64250 Itxassou France For further information please refer to the instructions for use |
|||||||||||||||||||||||||||||||||
30 | Y | 1000042 | NIPRUSS 60mg 5 ampoules | Lyophilizate for the preparation of an infusion solution. |
Composition Medically active ingredient 1 ampoule containing 52.75 mg lyophilizate for the preparation of an infusion solution contains nitroprusside sodium, anhydrous (corresponding to 60 mg nitroprusside sodium 2 H2O). Other ingredients: None. Indications Hypertensive crises, controlled hypotension during surgery. Contraindications: Nipruss must not be used if you are allergic to nitroprusside sodium; in cases of congenital pathological narrowing of the aorta in the transition area of the aortic arch to the main aortic branch (aortic isthmic stenosis); in cases of hereditary atrophy of fibers of the optic nerve (Leber's optic atrophy); in cases of bilateral, usually irreversible visual loss in color perception due to chronic tobacco abuse (tobacco amblyopia); in cases of vitamin B12 deficiency; in cases of metabolic acidosis of the blood and body (metabolic acidosis); in cases of hypothyroidism; in cases of existing short-circuit connection between arterial and venous blood vessels within the lungs (intra-pulmonary arteriovenous shunts). Side effects Feeling of weakness, dizziness, nausea, vomiting, tachycardia. Indications of cyanide poisoning: bright red venous blood, hypoventilation, lactate increase, decreased oxygen uptake, palpitations, headache, metabolic acidosis, coma, cardiac arrhythmias, respiratory paralysis, and convulsions. Deaths have been described. Cyanide poisoning is completely preventable with concurrent infusion of sodium thiosulfate. Inadequate blood pressure reduction and occurrence of tachyphylaxis or tolerance are more likely in younger than in older hypertensives. Warnings Keep drug out of reach of children. Prescription Only. Pharmaceutical entrepreneur ALTAMEDICS GmbH, Josef-Lammerting-Allee 16, D-50933 Cologne, Germany. For further information and warnings and precautions, please refer to the SmPC. |
||||||||||||||||||||||||||||||||
31 | Y | 1000086 | Restoric supportive S Vegan - 24 pieces |
Food for special medical purposes (balanced diet) for dietary management in cases of existing or threatened malnutrition as well as in cases of food intake disorders: high-protein, high-calorie, completely balanced drinkable food with dietary fiber. Properties restoric supportiv S Vegan supports dietary management in cases of existing or impending malnutrition as well as in cases of food intake disorders. The drinkable food is specially adapted to the needs of patients with malnutrition due to illness or age:
How much restoric supportiv S Vegan should be taken - and when? The amount to be taken depends on the degree of malnutrition and is prescribed by the doctor.
For exclusive nutrition, the dosage is to be calculated according to the individual energy requirement. restoric supportiv S Vegan should be taken as a snack. The intake of restoric supportiv S Vegan can take place at any time. In case of supplementary nutrition, the drinkable food should be taken as a snack. In this case, restoric supportiv S Vegan can be taken as a second breakfast, in the afternoon or before going to bed. It is recommended to drink the supplementary food one hour after a main meal rather than one hour before a larger meal. |
|||||||||||||||||||||||||||||||||
33 | Y | 2000001 | HyaloFast | Hyalofast® is a 3D nonwoven scaffold made of HYAFF® fibers |
Available in sizes 2x2cm and 5x5cm. In combination with mesenchymal stem cells (MSCs), it supports the regeneration of hyaline cartilage. Effective Excellent clinical and mid-term MRI results in the treatment of osteochondral defects of the ankle and knee. Hyaline-like cartilage confirmed by MRI T2 mapping Versatile Functions as a scaffold for bone marrow aspirate or as a chondroprotective cover after microfracture or perforation procedure Safe Not of animal origin. Excellent safety profile based on over 15 years of experience with HYAFF® products in clinical applications Excellent handling properties
Safe and bio-absorbable HyaloFast has been used in tissue regeneration for more than 15 years and has an excellent safety profile. When HYAFF is degraded to HS, it is naturally absorbed into the body. HyaloFast is not an animal product. Cell carrier that can be used in a variety of ways for cartilage regeneration. HyaloFast with microfacturing HyaloFast overcomes the challenge by acting as a chondroprotective cover that ensures MSC remain in situ after mobilization and promotes the formation of a stable and adhesive blood clot that fills the cartilage damage. HyaloFast with bone marrow aspirate concentrate (BMAC) HyaloFast supports bone marrow aspirate, which can be applied to HyaloFast. Thanks to its hydrophilic properties, HyaloFast allows rapid and homogeneous distribution of BMAC fluid. HyaloFast Indications HyaloFast carries the CE mark for the harvesting of mesenchymal stem cells for the treatment of chondral and osteochondral lesions. Hyalofast® is indicated for the treatment of chondral or osteochondral defects:
Caused by:
|
||||||||||||||||||||||||||||||||
34 | Y | 2000002 | Marrow Cellution RAN 11C - 11 G Knochenmark Entnahme System |
MARROW CELLUTION™ is an innovative instrument for the aspiration of bone marrow and cancellous bone. MARROW CELLUTION™ enables aspiration of bone marrow with high cellular content One puncture - multiple aspiration sites in the marrow space INNOVATION Reduces peripheral blood contamination - Closed system - Controlled movement of the cannula in the space EFFICIENCY Minimally invasive - One puncture - Many aspirates - Low aspirate volume - High cell yield - No centrifugation required PERFORMANCE Higher CFU-f count per ml - Simultaneous recovery of autologous bone graft - Sterile environment is not left |
|||||||||||||||||||||||||||||||||
35 | Y | 2000003 | Marrow Cellution MC-RAN-8C | SPONGIOSA Extraction |
MARROW CELLUTION™ is an innovative instrument for the aspiration of bone marrow and cancellous bone. MARROW CELLUTION™ enables aspiration of bone marrow with high cellular content One puncture - multiple aspiration sites in the marrow space INNOVATION Reduces peripheral blood contamination - Closed system - Controlled movement of the cannula in the space EFFICIENCY Minimally invasive - One puncture - Many aspirates - Low aspirate volume - High cell yield - No centrifugation required PERFORMANCE Higher CFU-f count per ml - Simultaneous recovery of autologous bone graft - Sterile environment is not left |
||||||||||||||||||||||||||||||||
38 | Y | 2000006 | SeraSeal | What is SeraSeal™? |
SeraSeal TM supports and catalyzes the patient's own blood clotting during the formation of a blood clot and stops bleeding, without applying pressure, within 30 seconds. SeraSeal TM contains inert agar polysaccharide/carbohydrate and bovine plasma-derived clotting factors. How SeraSeal is used SeraSeal is indicated for the control/stopping of hemorrhages (arterial and venous) of parenchymal organs, oozing hemorrhages, capillary hemorrhages, vascular anastomoses, etc., occurring in invasive, semi-invasive, and non-invasive procedures. SeraSeal is particularly applicable in surgical procedures. How SeraSeal works Blood clot formation is initiated by the release of tissue thromboplastin. This trigger initiates a series of reactions collectively known as the "coagulation cascade." Proven effectiveness The effectiveness of SeraSeal TM has been proven in several studies. Even in cases of difficult-to-control bleeding in the gastrointestinal tract, bleeding was completely stopped in 87% of patients using SeraSeal. Dosage forms SeraSeal 5 ml ampoule SeraSeal 3 ml ampoule SeraSeal 1.5 ml ampoule |
||||||||||||||||||||||||||||||||
39 | Y | 2000011 | Serumwerk - Eye Lotion BSS 500 ml PP bottle | Eye-Lotion Balanced salt solution |
Eye-Lotion Balanced salt solution - Rinsing solutions for safe and economical treatment during ophthalmic procedures Application Sterile irrigation solution for intraocular use during surgical procedures or for external moistening of the cornea Proven manufacturing processes and the highest level of safety and reliability in the handling of pharmaceuticals and medical devices are the basic requirements for our ophthalmic irrigation solution Properties
|
||||||||||||||||||||||||||||||||
40 | Y | 2000012 | VitaPES 210 HF Dialysator |
VitaPES® dialyzers for the complex requirements of effective and safe treatment of chronic renal failure. Properties
Development MTP Medical Technologies GmbH Pirna, as a subsidiary of Serumwerk Bernburg AG, has been developing and producing high-quality medical products for hemodialysis since 2007. In this specific case, 3 different dialyzers of the VitaPES® product line (Low, Balanced and High Flux) were developed. The outstanding performance properties of the Purema® hollow fiber membrane are based on the process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). S.E.T. leads to a significant improvement in the separation properties of the membrane, which filters out harmful substances from the blood. Technical innovation The unprecedented performance characteristics of Purema® are based on the breakthrough process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). The proprietary Sieving Enhancing Technology (S.E.T.) achieves membrane structures with significantly more uniform pore diameters and pore distribution than conventional synthetic membranes. S.E.T. thus leads to a significant improvement in the separation properties of the membrane. Medical innovation The properties of Purema® have been tailored to achieve both targeted elimination of agent molecules and improved clearance of low molecular weight uremic toxins. Dose and quality of dialysis treatment at the highest level together with perfect biocompatibility are important prerequisites to avoid immunological changes that may pose an increased risk to the patient. In this way, optimal dialysis can help to improve the patient's nutritional status prevent infections reduce the hospitalization rate improve the long-term survival rate. |
|||||||||||||||||||||||||||||||||
41 | Y | 2000014 | Port cannulas SFN1835B, straight with snout, G15 | SFN port cannula straight / special |
Special trocar ground needle for implantable port catheter systems and drug pump systems. Non-punching needle Special puncture cannulae for implanted port catheter systems made of medical steel with non-punching special ground joint, either with Luer lock attachment or optional connecting tube, handle or fixation wings. Indications Via port catheter system continuous or intermittent supply of drugs, infusion solutions, blood transfusions, blood sampling, parenteral nutrition, pain therapy, central venous pressure measurement, etc. Different diameters and stitch lengths are available depending on the application and necessary flow rate. Advantages due to special grinding with trocar tip and lateral exit hole
Product information SFN 1835 B Ø1.8 mm L=35 mm Gauge 15 straight with Luer/Lock attachment (with tube) Packaging unit (PU) 25 pieces |
||||||||||||||||||||||||||||||||
42 | Y | 2000015 | Port cannulas SFN1535B - 17G; 1.50x35 mm with tubing | SFN port cannula straight / special |
Special trocar ground needle for implantable port catheter systems and drug pump systems. Non-punching needle Special puncture cannulae for implanted port catheter systems made of medical steel with non-punching special ground joint, either with Luer lock attachment or optional connecting tube, handle or fixation wings. Indications Via port catheter system continuous or intermittent supply of drugs, infusion solutions, blood transfusions, blood sampling, parenteral nutrition, pain therapy, central venous pressure measurement, etc. Different diameters and stitch lengths are available depending on the application and necessary flow rate. Advantages due to special grinding with trocar tip and lateral exit hole
Product information SFN 1535 B Ø1.5 mm L=35 mm Gauge17 straight with Luer/Lock connector (with tubing) Packaging unit (PU) 25 pieces |
||||||||||||||||||||||||||||||||
43 | Y | 2000017 | Titanium port APH /Apheresis) w. single lumen silicone catheter 10F |
TITAN-PORT APH (extracorporeal apheresis) is a fully implantable titanium PORT system as an access device for performing extracorporeal apheresis. The set includes - port chambers with a self-sealing silicone membrane - a single-lumen silicone catheter with a connection to the port chamber - a screw to fix the catheter to the outflow tube - a special puncture cannula, an introducer, a tunnelizer, instructions for use and a patient passport In order to achieve the blood volume required for apheresis, appropriately large-volume cannulas are required, e.g. DPK 1835 and DPK 2035 or SFN 1535 G. These are distinguished by a special loop. These are characterized by a special grinding to avoid fragmentation of silicone particles and punching of a puncture channel in the membrane. A corresponding cannula is included with each system. Product information
|
|||||||||||||||||||||||||||||||||
44 | Y | 2000025 | Disposable spray catheter w. metal tip, sterile, 1.8x1200mm, 10pcs. |
Description Ø and length: 1.8 x 1200mm sterile working channel: 2.00mm 10 pieces per package |
|||||||||||||||||||||||||||||||||
45 | Y | 2000027 | Disposable spray catheter w. metal tip, sterile, 1.8x2300 mm, 10 pcs. |
Description Ø and length: 1.8 x 2300mm working channel: 2.00mm sterile 10 pieces per package |
|||||||||||||||||||||||||||||||||
46 | Y | 2000031 | Disposable spray catheter w. metal tip 2.4 x 2300 mm |
Description Ø and length: 2,4 x 2300mm sterile Working channel: 2.80mm 10 pieces per package |
|||||||||||||||||||||||||||||||||
47 | Y | 2000045 | VitaPES LF 22 Plus Dialysator |
VitaPES® dialyzers for the complex requirements of effective and safe treatment of chronic renal failure. The excellent properties of our VitaPES® dialyzers, which have been confirmed in clinical practice, are the result of innovative product development and modern production technology. Properties
VitaPES® dialyzers with excellent performance characteristics based on PUREMA membrane ensure excellent treatment of dialysis patients with high performance stability over the treatment period due to minimal immunological change and protein adsorption. Product information Ultrafiltration coefficient /ml/h/mmHg) 23 Surface area (m²) 2.1 Filling volume (ml) 119 |
|||||||||||||||||||||||||||||||||
48 | Y | 2000046 | VitaPES 150 HF Dialysator |
VitaPES® dialyzers for the complex requirements of effective and safe treatment of chronic renal failure. Properties
Development
MTP Medical Technologies GmbH Pirna, as a subsidiary of Serumwerk Bernburg AG, has been developing and producing high-quality medical products for hemodialysis since 2007. In this specific case, 3 different dialyzers of the VitaPES® product line (Low, Balanced and High Flux) were developed. The outstanding performance characteristics of the Purema® hollow fiber membrane are based on the process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). S.E.T. leads to a significant improvement in the separation properties of the membrane, which filters out harmful substances from the blood. Technical innovation The unprecedented performance characteristics of Purema® are based on the breakthrough process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). The proprietary Sieving Enhancing Technology (S.E.T.) achieves membrane structures with significantly more uniform pore diameters and pore distribution than conventional synthetic membranes. S.E.T. thus leads to a significant improvement in the separation properties of the membrane. Medical innovation The properties of Purema® have been tailored to achieve both targeted elimination of agent molecules and improved clearance of low molecular weight uremic toxins. Dose and quality of dialysis treatment at the highest level together with perfect biocompatibility are important prerequisites to avoid immunological changes that may pose an increased risk to the patient.
In this way, optimal dialysis can help to improve the patient's nutritional status prevent infections reduce the hospitalization rate improve the long-term survival rate. |
|||||||||||||||||||||||||||||||||
49 | Y | 2000047 | VitaPES 170 HF Dialysator |
VitaPES® dialyzers for the complex requirements of effective and safe treatment of chronic renal failure. Properties
Development
MTP Medical Technologies GmbH Pirna, as a subsidiary of Serumwerk Bernburg AG, has been developing and producing high-quality medical products for hemodialysis since 2007. In this specific case, 3 different dialyzers of the VitaPES® product line (Low, Balanced and High Flux) were developed. The outstanding performance characteristics of the Purema® hollow fiber membrane are based on the process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). S.E.T. leads to a significant improvement in the separation properties of the membrane, which filters out harmful substances from the blood. Technical innovation The unprecedented performance characteristics of Purema® are based on the breakthrough process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). The proprietary Sieving Enhancing Technology (S.E.T.) achieves membrane structures with significantly more uniform pore diameters and pore distribution than conventional synthetic membranes. S.E.T. thus leads to a significant improvement in the separation properties of the membrane. Medical innovation The properties of Purema® have been tailored to achieve both targeted elimination of agent molecules and improved clearance of low molecular weight uremic toxins. Dose and quality of dialysis treatment at the highest level together with perfect biocompatibility are important prerequisites to avoid immunological changes that may pose an increased risk to the patient.
In this way, optimal dialysis can help to improve the patient's nutritional status prevent infections reduce the hospitalization rate improve the long-term survival rate. |
|||||||||||||||||||||||||||||||||
50 | Y | 2000048 | VitaPES 190 HF Dialysator |
VitaPES® dialyzers for the complex requirements of effective and safe treatment of chronic renal failure. Properties
Development
MTP Medical Technologies GmbH Pirna, as a subsidiary of Serumwerk Bernburg AG, has been developing and producing high-quality medical products for hemodialysis since 2007. In this specific case, 3 different dialyzers of the VitaPES® product line (Low, Balanced and High Flux) were developed. The outstanding performance characteristics of the Purema® hollow fiber membrane are based on the process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). S.E.T. leads to a significant improvement in the separation properties of the membrane, which filters out harmful substances from the blood. Technical innovation The unprecedented performance characteristics of Purema® are based on the breakthrough process innovation of pore-forming S.E.T. technology (Sieving Enhancing Technology). The proprietary Sieving Enhancing Technology (S.E.T.) achieves membrane structures with significantly more uniform pore diameters and pore distribution than conventional synthetic membranes. S.E.T. thus leads to a significant improvement in the separation properties of the membrane. Medical innovation The properties of Purema® have been tailored to achieve both targeted elimination of agent molecules and improved clearance of low molecular weight uremic toxins. Dose and quality of dialysis treatment at the highest level together with perfect biocompatibility are important prerequisites to avoid immunological changes that may pose an increased risk to the patient.
In this way, optimal dialysis can help to improve the patient's nutritional status prevent infections reduce the hospitalization rate improve the long-term survival rate. |
|||||||||||||||||||||||||||||||||
51 | Y | 2000049 | Blood tubing system - AV/ for Nikkiso (code 1743) |
The vertical range of manufacture and the manufacturing know-how of the production facility, the MPH company, which is part of the Serumwerk Bernburg group of companies, meets the highest quality standards. With an extensive range of system variants for all common dialysis machines, we offer our customers maximum flexibility and independence.
Features
|
|||||||||||||||||||||||||||||||||
52 | Y | 2000050 | DiaCart - Bicarbonate cartridges 750g | Bicarbonate cartridges for hemodialysis |
DiaCart and DiaBox bicarbonate cartridges for all common dialysis machines with suitable cartridge holder. The bicarbonate cartridges represent a central component for the highest demands in the production of dialysis fluid. The following technical requirements are offered by the extensive cartridge delivery program:
|
||||||||||||||||||||||||||||||||
53 | Y | 2000051 | DiaCart - Bicarbonate cartridges 1100g | Bicarbonate cartridges for hemodialysis |
DiaCart and DiaBox bicarbonate cartridges for all common dialysis machines with suitable cartridge holder. The bicarbonate cartridges represent a central component for the highest demands in the production of dialysis fluid. The following technical requirements are offered by the extensive cartridge delivery program:
|
||||||||||||||||||||||||||||||||
54 | Y | 2000052 | Citric acid solution 50% - 5 liter canister |
With citric acid as the acidifying agent, this is the first significant change in dialysate formulation in more than thirty years, moving away from traditional formulations containing acetic acid. It is cleared by the FDA for all patients and is used in many clinics around the world.
Patient Benefits:
Product size Citric acid 10 liter canister, 60 pieces per pallet (weight approx. 760 kg) |
|||||||||||||||||||||||||||||||||
55 | Y | 2000053 | Citric acid solution 50% - 10 liter canister | Improves the treatment of all hemodialysis patients |
With citric acid as the acidifying agent, this is the first significant change in dialysate formulation in more than thirty years, moving away from traditional formulations containing acetic acid. It is cleared by the FDA for all patients and is used in many clinics around the world.
Patient Benefits:
Product size Citric acid 10 liter canister, 60 pieces per pallet (weight approx. 760 kg) |
||||||||||||||||||||||||||||||||
56 | Y | 2000054 | Surgical instruments bs LJCh - complete set | Surgical Instruments bs LJCh – complete Set |
Basic set for large joints An instrument for arthroscopic debridement of chondral lesions. The new tool allows maintaining a vertical section of the shoulder of the chondral lesion anywhere in human joints using an arthroscopic approach. Proper chondrectomy is critical prior to both bone marrow stimulation and implantation of matrices, as well as AMIC, MACI and other bioimplants. A perfect condylar chondrectomy Simply insert the chondrectome into the correct arthoscopic portal near the chondral defect. Instruments
Application Chondrectomes allow easy separation of damaged and calcified cartilage layer from the subchondral surface, at the same time the subchondral plate remains intact. The unique shape of the chondrectomes and special formation of the cutting edge allow precise modeling of the cartilage lesions and formation of vertical walls on the defect. The tools can be used in any anatomical situation (from any approach direction) and open or arthroscopically. |
||||||||||||||||||||||||||||||||
57 | Y | 2000069 | Port cannula DPK 2035, G 14 |
Special trocar ground needle for implantable port catheter systems and drug pump systems. Non-punching needle Special puncture cannulae for implanted port catheter systems made of medical steel with non-punching special ground joint, either with Luer lock attachment or optional connecting tube, handle or fixation wings. Indications Via port catheter system continuous or intermittent supply of drugs, infusion solutions, blood transfusions, blood sampling, parenteral nutrition, pain therapy, central venous pressure measurement, etc. Different diameters and stitch lengths are available depending on the application and necessary flow rate. Advantages due to special grinding with trocar tip and lateral exit hole
Product information DPK 2035 Ø 2,0 mm L=35 mm Gauge 14 with Mandarin + Needle Free Adapter Packaging unit (PU) 25 pieces |
|||||||||||||||||||||||||||||||||
58 | Y | 2000070 | SFN Port cannula 0930B | SFN port cannula straight / special |
Special trocar ground needle for implantable port catheter systems and drug pump systems. Non-punching needle Special puncture cannulae for implanted port catheter systems made of medical steel with non-punching special ground joint, either with Luer lock attachment or optional connecting tube, handle or fixation wings. Indications Via port catheter system continuous or intermittent supply of drugs, infusion solutions, blood transfusions, blood sampling, parenteral nutrition, pain therapy, central venous pressure measurement, etc. Different diameters and stitch lengths are available depending on the application and necessary flow rate. Advantages due to special grinding with trocar tip and lateral exit hole
Product information SFN 0930 B Ø 0,9mm L=30mm Gauge 20 straight with Luer/Lock connector (with tubing) Packaging unit (PU) 25 pieces |
||||||||||||||||||||||||||||||||
60 | Y | 2000083 | Titanport D-dialysis port system (set incl. introducer set and tunnelizer) with double 14 F catheter | Dialysis port system (set incl. insertion set and tunnelizer) |
TITAN-PORT D (Dialysis) is a fully implantable titanium PORT system as an access device for performing veno-venous dialysis. Product information
Depending on the product, the set contains
In order to achieve the blood flow rate required for dialysis purposes, appropriately large-volume cannulas are required, e.g. DPK 1835 and DPK 2035. These are characterized by a special grinding to prevent fragmentation of silicone particles and punching out of a puncture channel in the membrane. Suitable cannulas are included with each system. |
||||||||||||||||||||||||||||||||
61 | Y | 2000084 | Surgical instruments bs LJIm - complete set | Surgical Instruments bs LJIm – complete Set |
An instrument for arthroscopic debridement of chondral lesions. The new tool allows maintaining a vertical section of the shoulder of the chondral lesion anywhere in human joints using an arthroscopic approach. Proper chondrectomy is critical prior to both bone marrow stimulation and implantation of matrices, as well as AMIC, MACI and other bioimplants. A perfect condylar chondrectomy Simply insert the chondrectome into the correct arthoscopic portal near the chondral defect.
Instruments
Additional instruments:
The half-tube guide helps to insert the bioimplant into the joint cavity through the outer body layer. In addition, it provides pressure equalization during dry arthroscopy.
The Bio Implant Inserter enables the insertion of bioimplants into the joint cavity via an arthroscopic portal using a half-tube guide.
A plate wound spreader is used to expose the joint capsule including soft tissue, thus creating the necessary working space within the joint cavity during dry arthroscopy. Exposure is achieved by means of a thread pulled through the skin and connected to the plate wound retractor.
The curved raspatory is used to compress matrix or bone marrow at the site of the defect and finally to sculpt the surface.
The bone marrow guide (inserter) is used to implant bone marrow into the bone cyst or at the site of the defect. The tool enables compaction of the bone marrow during implantation. The bone marrow guide consists of a cylinder, a pusher and a loader. Application Chondrectomes allow easy separation of the damaged and calcified cartilage layer from the subchondral surface, while leaving the subchondral plate intact. The unique shape of the chondrectomes and special formation of the cutting edge allow precise modeling of the cartilage lesions and formation of vertical walls on the defect. The tools can be used in any anatomical situation (from any approach direction) and open or arthroscopically. |
||||||||||||||||||||||||||||||||
62 | Y | 2000089 | Surgical instruments bs sJCh - complete set | Surgical Instruments bs sJCh – complete Set |
Basic set for small joints An instrument for arthroscopic debridement of chondral lesions. The new tool allows maintaining a vertical section of the shoulder of the chondral lesion anywhere in human joints using an arthroscopic approach. Proper chondrectomy is critical prior to both bone marrow stimulation and implantation of matrices, as well as AMIC, MACI and other bioimplants. A perfect condylar chondrectomy Simply insert the chondrectome into the correct arthoscopic portal near the chondral defect. Instruments
Application Chondrectomes allow easy separation of damaged and calcified cartilage layer from the subchondral surface, at the same time the subchondral plate remains intact. The unique shape of the chondrectomes and special formation of the cutting edge allow precise modeling of the cartilage lesions and formation of vertical walls on the defect. The tools can be used in any anatomical situation (from any approach direction) and open or arthroscopically. |
||||||||||||||||||||||||||||||||
63 | Y | 2000090 | Surgical instruments bs sIm - complete set | Surgical Instruments bs slm – complete Set |
An instrument for arthroscopic debridement of chondral lesions. The new tool allows maintaining a vertical section of the shoulder of the chondral lesion anywhere in human joints using an arthroscopic approach. Proper chondrectomy is critical prior to both bone marrow stimulation and implantation of matrices, as well as AMIC, MACI and other bioimplants. A perfect condylar chondrectomy Simply insert the chondrectome into the correct arthoscopic portal near the chondral defect. Instruments
Additional instruments:
The half-tube guide helps to insert the bioimplant into the joint cavity through the outer body layer. In addition, it provides pressure equalization during dry arthroscopy.
FFB833
A plate wound retractor is used to expose the joint capsule including soft tissue, thus creating the necessary working space within the joint cavity during dry arthroscopy. Exposure is achieved by means of a thread pulled through the skin and connected to the plate wound retractor.
The curved raspatory is used to compress matrix or bone marrow at the site of the defect and finally to sculpt the surface.
The bone marrow guide (inserter) is used to implant bone marrow into the bone cyst or at the site of the defect. The tool enables compaction of the bone marrow during implantation. The bone marrow guide consists of a cylinder, a pusher and a loader. Application Chondrectomes allow easy separation of the damaged and calcified cartilage layer from the subchondral surface, while leaving the subchondral plate intact. The unique shape of the chondrectomes and special formation of the cutting edge allow precise modeling of the cartilage lesions and formation of vertical walls on the defect. The tools can be used in any anatomical situation (from any approach direction) and open or arthroscopically. |
||||||||||||||||||||||||||||||||
64 | Y | 2000096 | SFN 1320 S 20 mm/18G gebogen mit Luer/Lock mit Schlauch |
Especially for blood sampling, transfusion, contrast medium injection*, apheresis and high pressure injection. SFN 1320 S - Features Ø/mm - 1.3 L/mm – 20 Gauge - 22 Punch-free needle
|
|||||||||||||||||||||||||||||||||
65 | Y | 2000100 | Mouth-nose protection 3-ply |
A 3-layer medical face mask with integrated nose clip for maximum user comfort. Description
|
|||||||||||||||||||||||||||||||||
66 | Y | 2000105 | PCL COVID-19 Ag Gold Saliva Test - 50 pieces |
The PCL Spit Rapid Spit Test is an in vitro diagnostic medical device based on a rapid immunochromatographic assay (ICA) procedure and is designed for the qualitative detection of SARS-CoV-2 antigens in human saliva specimens. Available in the following packaging units: 1 pc. Pack, 5 pcs. Pack and 50 pcs. Pack Specimen collection
|
|||||||||||||||||||||||||||||||||
67 | Y | 2000108 | PCL COVID-19 Ag Gold Saliva Test - 1 piece |
The PCL Spit Rapid Spit Test is an in vitro diagnostic medical device based on a rapid immunochromatographic assay (ICA) procedure and is designed for the qualitative detection of SARS-CoV-2 antigens in human saliva specimens. Available in the following packaging units: 1 pc. Pack, 5 pcs. Pack and 50 pcs. Pack Specimen collection
|
|||||||||||||||||||||||||||||||||
68 | Y | 2000110 | Respirator mask FFP2 without valve TYPE YY0525/2163-PPE-834 |
High quality self and external protection, good wearing comfort, high breathability due to high quality fleece materials and extra strong and flexible nose clip CE MARKING - NB 2163 Product details Name: Respirator, FFP2 without valve Type: YY0525 Category: PPE category III Equipment class: FFP2 NR (Non Reusable) Quantity/packing unit: Individually packed, in 25 pieces package Color: White Storage conditions: Do not store below 0°C or above 40°C and in a dry place without direct sunlight Size Mask:16x11cm when folded (Slight variations in size possible) Weight (per mask): approx. 6.00g (Slight variations possible) Certification: EN 149:2001+A1:2009, Declaration of Conformity (EU 2016/425) Instructions for use Minimum durability: see mask For use according to PPE regulation It is recommended to take off and change the respirator every 4 hours or in case of moisture penetration Not reusable |
|||||||||||||||||||||||||||||||||
69 | Y | 2000111 | Respirator FFP 2 without valve TYPE HY-9320 FFP2 NR |
These high quality HY9320 FFP2 respirators offer 94% filtration against harmful particles, combine a lightweight design and certified safety to provide safe and comfortable respiratory protection. Designed with comfort and safety in mind, these disposable respirators provide a tight seal thanks to their adjustable nose bridge. The elastic strap is held in place by sturdy plastic clips to ensure the mask is secure at all times. Supplied in a box of 20 pieces. Description
|
|||||||||||||||||||||||||||||||||
70 | Y | 2000115 | Respirator mask FFP2 without valve TYPE SNN70369B FFP 2 NR |
These certified, particle-filtering half masks FFP2 for self and external protection against particles, droplets as well as solid or liquid aerosols are certified according to the standard EN 149:2001 + A1:2009 and belong to PPE (Personal Protective Equipment) Class III. Thus, the masks comply with EN 149:2001+A1:2009 according to the PPE Regulation (EU) 2016/425. CE- certification available! Product features
Product information Item weight: 0.18 grams Package dimensions: 18.9 x 14.3 x 13.7 cm; 400 grams For the flat folded mask, the width is about 11 cm and the long vertical side is about 16 cm. The height of a mask double pack is about 1.5 cm. |
|||||||||||||||||||||||||||||||||
71 | Y | 2000119 | Respirator mask FFP 3 without valve TYPE HY-9330 FFP3 NR |
These respirators HY9330 FFP3 have a unique three-piece design and combine comfort, protection and functionality. They allow for plenty of movement while maintaining safety and are designed to prevent slipping. These high quality HY9330 FFP3 respirators combine a lightweight design and certified safety to provide safe and comfortable respiratory protection. They are ideal as medical personal protective equipment for primary and ambulatory patients, as well as in community and social service settings. Description
Packaging Description HYGIENIC PACKAGING: Protects the respirator from contamination before use, also allows convenient storage and dispensing in the workplace. |
|||||||||||||||||||||||||||||||||
72 | Y | 2000122 | Mouth-nose protection (with ear loops) - Type IIR, KF-BP01 |
This disposable multi-layer surgical quality face mask is ideal for professional or personal use! Thanks to the deformable nosepiece and stretchable elastics, it fits both men and women and can be ideally adapted to any face. Approved according to EN 14683 Description STANDARD QUALITY: Approved according to EN 14683 (medical face masks), AC (type IIR)! MULTI-LAYER: The double layer material of our face mask increases the safety. Please wear the mask to completely cover your nose and mouth to reduce the spread of droplets SPACE SAVING: The Kingfa MNS is extra flat for easy storage in any pants pocket or handbag. Ideal as a spare, to take with you and as a display for customers / visitors! Package dimensions: 19 x 10 x 8 cm - 150grams |
|||||||||||||||||||||||||||||||||
73 | Y | 2000123 | FFP2 Respirator mask without valve - KF-A F10 (SC) |
The FFP2 mask can be fastened with ear loops and offers a secure fit. It ensures a very high level of protection for the wearer, but also for the person in front of him. Since the KINGFA KF-A F10 mask does not have a valve, it filters the exhaled as well as the inhaled air according to the EN 149 standard. Furthermore, the mask complies with the EU regulation 2016/425 and is thus a product of the Personal Protective Equipment category III (PPE). Product data
|
|||||||||||||||||||||||||||||||||
74 | Y | 2000124 | FFP3 Respirator mask without valve - KF-A F11 (RF-TD-3) |
The 5-layer, filtering mouth and nose protection is characterized by the pleasant, with adjustable nose wing easily adjustable fit and high wearing comfort. The protective masks of FFP3 quality, protect against bacteria, and germs! Thanks to the existing rubber bands (head), the mask sits firmly without slipping off. Product data
|
|||||||||||||||||||||||||||||||||
75 | Y | 2000132 | Achilles Tendon FZ/I w/ Bone Block >14cm | Bänder und Sehnen |
Graft: Achilles Description
|
||||||||||||||||||||||||||||||||
76 | Y | 2000133 | Patella Ligament Whole FZ/I | Bänder und Sehnen |
Graft: Patellar Ligament Description
|
||||||||||||||||||||||||||||||||
77 | Y | 2000134 | Tibialis Tendon Anterior FZ/I - Double Strand >23 cm in Length | Ligaments and tendons |
Graft: Tibialis Anteroir Description: Double Strand
|
||||||||||||||||||||||||||||||||
78 | Y | 2000135 | Allo Pac - Purged 25 cc (1-4 mm cortical particle size, 1-9,5 mm cancellous particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
79 | Y | 2000136 | Peroneous Longus FZ/I - Double Strand > 23cm in Lenght | Ligaments and tendons |
Graft: Peroneus Longus Description
|
||||||||||||||||||||||||||||||||
80 | Y | 2000137 | Allo Pac - Purged 50 cc (1-4 mm cortical particle size, 1-9,5 mm cancellous particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
81 | Y | 2000138 | Allo Pac - Purged 100 cc (1-4 mm cortical particle size, 1-9,5 mm cancellous particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
82 | Y | 2000139 | Cancellous Chips 15 cc (4-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
83 | Y | 2000140 | Cancellous Chips 30 cc (4-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
84 | Y | 2000141 | Cancellous Chips 60 cc (4-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
85 | Y | 2000142 | Cancellous Chips 90 cc (4-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
86 | Y | 2000143 | Cancellous Chips 15 cc (1-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
87 | Y | 2000144 | Cancellous Chips 30 cc (1-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
88 | Y | 2000145 | Cancellous Chips 50 cc (1-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
89 | Y | 2000146 | Cancellous Chips 90 cc (1-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
90 | Y | 2000147 | Cancellous Crushed 15 cc (1-4 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
91 | Y | 2000148 | Cancellous Crushed 30 cc (1-4 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
92 | Y | 2000149 | Cancellous Crushed 60 cc (1-4 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
93 | Y | 2000150 | Cancellous Cubes 15 cc (1 cm³ cube size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
94 | Y | 2000151 | Cancellous Cubes 30 cc (1 cm³ cube size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
95 | Y | 2000152 | Cancellous Block 3 x 1,5 cm | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
96 | Y | 2000153 | Cortical/Cancellous Chips 15 cc (1-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
97 | Y | 2000154 | Cortical/Cancellous Chips 30 cc (1-9,5 mm particle size) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
98 | Y | 2000155 | Femoral Heads w/o Cartilage (D <4,7 cm) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
99 | Y | 2000156 | Femoral Heads w/o Cartilage (D >4,8 cm) | Bone Cortical and Cancellous Bone |
Description
|
||||||||||||||||||||||||||||||||
100 | Y | 2000157 | AlloFuse Cortical Fibers 1 cc (Demineralized Bone Fiber Technology) | Bone fibers I Cartilage |
Description
|
||||||||||||||||||||||||||||||||
101 | Y | 2000158 | AlloFuse Cortical Fibers 5 cc (Demineralized Bone Fiber Technology) | Bone fibers I Cartilage |
Description
|
||||||||||||||||||||||||||||||||
102 | Y | 2000159 | AlloFuse Cortical Fibers 10 cc (Demineralized Bone Fiber Technology) | Bone fibers I Cartilage |
Description
|
||||||||||||||||||||||||||||||||
103 | Y | 2000160 | AlloFuse Fiber Boat 5 cc, small 50 x 25 mm (Demineralized Bone Fiber Technology) | Bone fibers I Cartilage |
Description
|
||||||||||||||||||||||||||||||||
104 | Y | 2000161 | AlloFuse Fiber Boat 10 cc, large 100 x 25 mm (Demineralized Bone Fiber Technology) | (Demineralized Bone Fiber Technology) Bone Fibers I Cartilage |
Description
|
||||||||||||||||||||||||||||||||
105 | Y | 2000162 | AlloFlex Filler 2,5 cc (1-4 mm particle size) - Partially Demineralized Cancellous Bone | Cellular Bone I DBMs |
Description
|
||||||||||||||||||||||||||||||||
106 | Y | 2000163 | AlloFlex Filler 5 cc (1-4 mm particle size) - Partially Demineralized Cancellous Bone | (1-4 mm particle size) Cellular bone I DBMs |
Description
|
||||||||||||||||||||||||||||||||
107 | Y | 2000164 | AlloFlex Filler 10 cc (1-4 mm particle size) - Partially Demineralized Cancellous Bone | (1-4 mm particle size) Cellular bone I DBMs |
Description
|
||||||||||||||||||||||||||||||||
108 | Y | 2000165 | AlloFuse DBM Putty 1 cc (Demineralized Bone Matrix) | Demineralized bone matrix (DBMs) |
Description
|
||||||||||||||||||||||||||||||||
109 | Y | 2000166 | AlloFuse DBM Putty 2,5 cc (Demineralized Bone Matrix) | Demineralized bone matrix (DBMs) |
Description
|
||||||||||||||||||||||||||||||||
110 | Y | 2000167 | AlloFuse DBM Putty 5 cc (Demineralized Bone Matrix) | Demineralized bone matrix (DBMs) |
Description
|
||||||||||||||||||||||||||||||||
111 | Y | 2000168 | AlloFuse DBM Putty 10 cc (Demineralized Bone Matrix) | Demineralized bone matrix (DBMs) |
Description
|
||||||||||||||||||||||||||||||||
112 | Y | 2000169 | AlloFuse Plus DBM Paste 1 cc (Demineralized Bone Matrix with Cancellous) | Demineralized bone matrix with cancellous bone |
Description
|
||||||||||||||||||||||||||||||||
113 | Y | 2000170 | AlloFuse Plus DBM Paste 3 cc (Demineralized Bone Matrix with Cancellous) | Demineralized bone matrix with cancellous bone |
Description
|
||||||||||||||||||||||||||||||||
114 | Y | 2000171 | AlloFuse Plus DBM Paste 8 cc (Demineralized Bone Matrix with Cancellous) | Demineralized bone matrix with cancellous bone |
Description
|
||||||||||||||||||||||||||||||||
115 | Y | 2000172 | AlloGro DBM 10 cc (125-710 micron particle size) - Demineralized Bone Matrix | Demineralized bone matrix (DBMs) |
Description
|
||||||||||||||||||||||||||||||||
116 | Y | 2000173 | FURS-0100 Nano FX Thumble - 5 pieces | NANOFRACTURING WITH NANOFX® |
Microfracturing is increasingly criticized as a treatment option for focal cartilage defects and, according to professional societies and cartilage experts, should only be used in exceptional cases. Nanofracturing offers an effective alternative for the treatment of chondral and osteochondral defects. NanoFx® is a bone marrow stimulation system that provides a standardized procedure for nanofracturing. Deep perforation of the subchondral plate and sub-articular cancellous bone creates direct access channels into the medullary canal through which mesenchymal stem cells (MSCs) can infiltrate into the cartilage defect. This bleeding in with accompanying recruitment of MSC is a prerequisite for cartilage regeneration. Due to the 9 mm deep perforation using NanoFx®, high yields of MSC can be achieved, promoting high-quality cartilage regeneration with a hyaline-like character. In addition, due to the 1 mm thin diameter, the subchondral plate and cancellous bone are spared, with the aim of promoting rapid healing and restoration of the subchondral bone. ADVANTAGES OF NANOFRACTURING
NANOFX® AND HYALOFAST® CONVINCING ONE-STEP CARTILAGE REGENERATION WITH THE COMBINATION OF NANOFX® AND HYALOFAST® NanoFx® and Hyalofast® offer a modern therapeutic concept for the treatment of chondral and osteochondral defects. Nanofracturing is a standardized procedure for the recruitment of mesenchymal stem cells (MSC) from the medullary canal. Matrix augmented cartilage regeneration with Hyalofast® promotes MSC differentiation to support chondrogenesis through the biological activity of hyaluronic acid. Thus, NanoFx® and Hyalofast® complement each other to form an optimal therapeutic concept for the treatment of cartilage defects.
FAST AND EASY APPLICATION The NanoFx® Guide can be inserted into the defect arthroscopically or minimally invasively and requires no specific incisions. With the sterile disposable needle, a sharp instrument is always at hand to perforate the subchondral plate. NanoFx® is easy to put together and therefore quickly ready for use. Compared to microfracturing, the force of the hammer blow is optimally transferred to the 1 mm thin tip of the needle, so that even light blows are sufficient. Due to the integrated depth limitation, the needle is always inserted into the cancellous bone to a depth of 9 mm in a controlled manner. Application of NanoFx®: Step 1: Insert the PleuriStik needle, tip down, through the opening of the Thumb Tab and through the proximal opening of the NanoFX® Guide without the needle being visible at the distal tip of the guide. Step 2: Place the tip of the NanoFx® Guide 2-3 mm in front of the intact cartilage wall away into the defect. Place the tip of the NanoFX® Guide only lightly on the subchondral plate. Step 3: Lightly tap the exposed proximal tip of the needle several times with a hammer to insert the needle into the defect to the depth limit of 9mm. Step 4: To retract the needle one-handed, press down on the thumb tab with your thumb. This will lever the PleuriStik needle out of the NanoFx® Guide. To perform additional perforations, reposition the guide and repeat steps 2-4. The NanoFx® Guide is reusable and must be cleaned and sterilized after use. NANOFX® SHORT AND COMPACT Product: NanoFx® - Instrument for bone marrow stimulation Article: NanoFx® Guide, PleuriStik Nitinol needle, Thumb Tab Approval: medical device with CE mark Sterilization: gamma sterilized Storage: store in a dry place DEVELOPMENT OF NANOFRACTURING Bone marrow stimulation to recruit progenitor cells into the cartilage defect is a well-established therapeutic option in cartilage regeneration. Since the late 1980s, microfracturing emerged as the primary treatment choice because of its low cost, relatively low morbidity, and encouraging results as an initial procedure for cartilage defects, especially in young and active patients (1-3). Renewed interest in the effects on subchondral bone shed new light on the limitations of microfracturing: shallow channels, wall compression, and an increase in trabecular wall thickness and density were observed computed tomographically and histologically (4-6). Chen et al. reported that deeper subchondral bone marrow stimulation resulted in improved cartilage defect filling, more type 2 collagen, and less type 1 collagen than shallow bone marrow access (5). A study by Eldracher et al (7), showed that 1 mm thin holes had improved histo- gy, cancellous bone restoration, and immunoreactivity to type 2 collagen compared to 1.8 mm wide holes. The nonstandard depth, diameter, and perforation density of microfracturing led to the development of a new method to perforate the subchondral plate (nanofracturing), which has a standardized depth of 9 mm and a diameter of 1 mm. LITERATURE Kreuz PC, Steinwachs MR, Erggelet C, Krause SJ, Konrad G, Uhl M, Südkamp N. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage. 2006 Nov;14(11):1119-25. Mithoefer K, Williams RJ 3rd, Warren RF, Potter HG, Spock CR, Jones EC, Wickiewicz TL, Marx RG. The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg Am. 2005 Sep;87(9):1911-20. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthroscopy. 2003 May-Jun;19(5):477-84. Chen H, Sun J, Hoemann CD, Lascau-Coman V, Ouyang W, McKee MD, Shive MS, Buschmann MD. Drilling and microfracture lead to different bone structure and necrosis during bone-marrow stimulation for cartilage repair. J Orthop Res. 2009 Nov;27(11):1432-8. Chen H, Hoemann CD, Sun J, Chevrier A, McKee MD, Shive MS, Hurtig M, Buschmann MD. Depth of subchondral perforation influences the outcome of bone marrow stimulation cartilage repair. J Orthop Res. 2011 Aug;29(8):1178-84. Fortier LA, Cole BJ, McIlwraith CW. Science and animal models of marrow stimulation for cartilage repair. J Knee Surg. 2012 Mar;25(1):3-8. Eldracher M. et al. Small Subchondral Drill Holes improve Marrow Stimulation of Articular Cartilage Defects. Am J Sports Med. 2014 Nov;42(11):2741-50. |
||||||||||||||||||||||||||||||||
117 | Y | 2000174 | FURS-2101 Nano FX Pleurstik - 5 pieces | NANOFRACTURING WITH NANOFX® |
Microfracturing is increasingly criticized as a treatment option for focal cartilage defects and, according to professional societies and cartilage experts, should only be used in exceptional cases. Nanofracturing offers an effective alternative for the treatment of chondral and osteochondral defects. NanoFx® is a bone marrow stimulation system that provides a standardized procedure for nanofracturing. Deep perforation of the subchondral plate and sub-articular cancellous bone creates direct access channels into the medullary canal through which mesenchymal stem cells (MSCs) can infiltrate into the cartilage defect. This bleeding in with accompanying recruitment of MSC is a prerequisite for cartilage regeneration. Due to the 9 mm deep perforation using NanoFx®, high yields of MSC can be achieved, promoting high-quality cartilage regeneration with a hyaline-like character. In addition, due to the 1 mm thin diameter, the subchondral plate and cancellous bone are spared, with the aim of promoting rapid healing and restoration of the subchondral bone. ADVANTAGES OF NANOFRACTURING
NANOFX® AND HYALOFAST® CONVINCING ONE-STEP CARTILAGE REGENERATION WITH THE COMBINATION OF NANOFX® AND HYALOFAST® NanoFx® and Hyalofast® offer a modern therapeutic concept for the treatment of chondral and osteochondral defects. Nanofracturing is a standardized procedure for the recruitment of mesenchymal stem cells (MSC) from the medullary canal. Matrix augmented cartilage regeneration with Hyalofast® promotes MSC differentiation to support chondrogenesis through the biological activity of hyaluronic acid. Thus, NanoFx® and Hyalofast® complement each other to form an optimal therapeutic concept for the treatment of cartilage defects.
FAST AND EASY APPLICATION The NanoFx® Guide can be inserted into the defect arthroscopically or minimally invasively and requires no specific incisions. With the sterile disposable needle, a sharp instrument is always at hand to perforate the subchondral plate. NanoFx® is easy to put together and therefore quickly ready for use. Compared to microfracturing, the force of the hammer blow is optimally transferred to the 1 mm thin tip of the needle, so that even light blows are sufficient. Due to the integrated depth limitation, the needle is always inserted into the cancellous bone to a depth of 9 mm in a controlled manner. Application of NanoFx®: Step 1: Insert the PleuriStik needle, tip down, through the opening of the Thumb Tab and through the proximal opening of the NanoFX® Guide without the needle being visible at the distal tip of the guide. Step 2: Place the tip of the NanoFx® Guide 2-3 mm in front of the intact cartilage wall away into the defect. Place the tip of the NanoFX® Guide only lightly on the subchondral plate. Step 3: Lightly tap the exposed proximal tip of the needle several times with a hammer to insert the needle into the defect to the depth limit of 9mm. Step 4: To retract the needle one-handed, press down on the thumb tab with your thumb. This will lever the PleuriStik needle out of the NanoFx® Guide. To perform additional perforations, reposition the guide and repeat steps 2-4. The NanoFx® Guide is reusable and must be cleaned and sterilized after use. NANOFX® SHORT AND COMPACT Product: NanoFx® - Instrument for bone marrow stimulation Article: NanoFx® Guide, PleuriStik Nitinol needle, Thumb Tab Approval: medical device with CE mark Sterilization: gamma sterilized Storage: store in a dry place DEVELOPMENT OF NANOFRACTURING Bone marrow stimulation to recruit progenitor cells into the cartilage defect is a well-established therapeutic option in cartilage regeneration. Since the late 1980s, microfracturing emerged as the primary treatment choice because of its low cost, relatively low morbidity, and encouraging results as an initial procedure for cartilage defects, especially in young and active patients (1-3). Renewed interest in the effects on subchondral bone shed new light on the limitations of microfracturing: shallow channels, wall compression, and an increase in trabecular wall thickness and density were observed computed tomographically and histologically (4-6). Chen et al. reported that deeper subchondral bone marrow stimulation resulted in improved cartilage defect filling, more type 2 collagen, and less type 1 collagen than shallow bone marrow access (5). A study by Eldracher et al (7), showed that 1 mm thin holes had improved histo- gy, cancellous bone restoration, and immunoreactivity to type 2 collagen compared to 1.8 mm wide holes. The nonstandard depth, diameter, and perforation density of microfracturing led to the development of a new method to perforate the subchondral plate (nanofracturing), which has a standardized depth of 9 mm and a diameter of 1 mm. LITERATURE Kreuz PC, Steinwachs MR, Erggelet C, Krause SJ, Konrad G, Uhl M, Südkamp N. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage. 2006 Nov;14(11):1119-25. Mithoefer K, Williams RJ 3rd, Warren RF, Potter HG, Spock CR, Jones EC, Wickiewicz TL, Marx RG. The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg Am. 2005 Sep;87(9):1911-20. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthroscopy. 2003 May-Jun;19(5):477-84. Chen H, Sun J, Hoemann CD, Lascau-Coman V, Ouyang W, McKee MD, Shive MS, Buschmann MD. Drilling and microfracture lead to different bone structure and necrosis during bone-marrow stimulation for cartilage repair. J Orthop Res. 2009 Nov;27(11):1432-8. Chen H, Hoemann CD, Sun J, Chevrier A, McKee MD, Shive MS, Hurtig M, Buschmann MD. Depth of subchondral perforation influences the outcome of bone marrow stimulation cartilage repair. J Orthop Res. 2011 Aug;29(8):1178-84. Fortier LA, Cole BJ, McIlwraith CW. Science and animal models of marrow stimulation for cartilage repair. J Knee Surg. 2012 Mar;25(1):3-8. Eldracher M. et al. Small Subchondral Drill Holes improve Marrow Stimulation of Articular Cartilage Defects. Am J Sports Med. 2014 Nov;42(11):2741-50. |
||||||||||||||||||||||||||||||||
118 | Y | 2000175 | FURS-4101 Nano FX Pleurstik A-Curve - 5 pieces | NANOFRACTURING WITH NANOFX® |
Microfracturing is increasingly criticized as a treatment option for focal cartilage defects and, according to professional societies and cartilage experts, should only be used in exceptional cases. Nanofracturing offers an effective alternative for the treatment of chondral and osteochondral defects. NanoFx® is a bone marrow stimulation system that provides a standardized procedure for nanofracturing. Deep perforation of the subchondral plate and sub-articular cancellous bone creates direct access channels into the medullary canal through which mesenchymal stem cells (MSCs) can infiltrate into the cartilage defect. This bleeding in with accompanying recruitment of MSC is a prerequisite for cartilage regeneration. Due to the 9 mm deep perforation using NanoFx®, high yields of MSC can be achieved, promoting high-quality cartilage regeneration with a hyaline-like character. In addition, due to the 1 mm thin diameter, the subchondral plate and cancellous bone are spared, with the aim of promoting rapid healing and restoration of the subchondral bone. ADVANTAGES OF NANOFRACTURING
NANOFX® AND HYALOFAST® CONVINCING ONE-STEP CARTILAGE REGENERATION WITH THE COMBINATION OF NANOFX® AND HYALOFAST® NanoFx® and Hyalofast® offer a modern therapeutic concept for the treatment of chondral and osteochondral defects. Nanofracturing is a standardized procedure for the recruitment of mesenchymal stem cells (MSC) from the medullary canal. Matrix augmented cartilage regeneration with Hyalofast® promotes MSC differentiation to support chondrogenesis through the biological activity of hyaluronic acid. Thus, NanoFx® and Hyalofast® complement each other to form an optimal therapeutic concept for the treatment of cartilage defects.
FAST AND EASY APPLICATION The NanoFx® Guide can be inserted into the defect arthroscopically or minimally invasively and requires no specific incisions. With the sterile disposable needle, a sharp instrument is always at hand to perforate the subchondral plate. NanoFx® is easy to put together and therefore quickly ready for use. Compared to microfracturing, the force of the hammer blow is optimally transferred to the 1 mm thin tip of the needle, so that even light blows are sufficient. Due to the integrated depth limitation, the needle is always inserted into the cancellous bone to a depth of 9 mm in a controlled manner. Application of NanoFx®: Step 1: Insert the PleuriStik needle, tip down, through the opening of the Thumb Tab and through the proximal opening of the NanoFX® Guide without the needle being visible at the distal tip of the guide. Step 2: Place the tip of the NanoFx® Guide 2-3 mm in front of the intact cartilage wall away into the defect. Place the tip of the NanoFX® Guide only lightly on the subchondral plate. Step 3: Lightly tap the exposed proximal tip of the needle several times with a hammer to insert the needle into the defect to the depth limit of 9mm. Step 4: To retract the needle one-handed, press down on the thumb tab with your thumb. This will lever the PleuriStik needle out of the NanoFx® Guide. To perform additional perforations, reposition the guide and repeat steps 2-4. The NanoFx® Guide is reusable and must be cleaned and sterilized after use. NANOFX® SHORT AND COMPACT Product: NanoFx® - Instrument for bone marrow stimulation Article: NanoFx® Guide, PleuriStik Nitinol needle, Thumb Tab Approval: medical device with CE mark Sterilization: gamma sterilized Storage: store in a dry place DEVELOPMENT OF NANOFRACTURING Bone marrow stimulation to recruit progenitor cells into the cartilage defect is a well-established therapeutic option in cartilage regeneration. Since the late 1980s, microfracturing emerged as the primary treatment choice because of its low cost, relatively low morbidity, and encouraging results as an initial procedure for cartilage defects, especially in young and active patients (1-3). Renewed interest in the effects on subchondral bone shed new light on the limitations of microfracturing: shallow channels, wall compression, and an increase in trabecular wall thickness and density were observed computed tomographically and histologically (4-6). Chen et al. reported that deeper subchondral bone marrow stimulation resulted in improved cartilage defect filling, more type 2 collagen, and less type 1 collagen than shallow bone marrow access (5). A study by Eldracher et al (7), showed that 1 mm thin holes had improved histo- gy, cancellous bone restoration, and immunoreactivity to type 2 collagen compared to 1.8 mm wide holes. The nonstandard depth, diameter, and perforation density of microfracturing led to the development of a new method to perforate the subchondral plate (nanofracturing), which has a standardized depth of 9 mm and a diameter of 1 mm. LITERATURE Kreuz PC, Steinwachs MR, Erggelet C, Krause SJ, Konrad G, Uhl M, Südkamp N. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage. 2006 Nov;14(11):1119-25. Mithoefer K, Williams RJ 3rd, Warren RF, Potter HG, Spock CR, Jones EC, Wickiewicz TL, Marx RG. The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg Am. 2005 Sep;87(9):1911-20. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthroscopy. 2003 May-Jun;19(5):477-84. Chen H, Sun J, Hoemann CD, Lascau-Coman V, Ouyang W, McKee MD, Shive MS, Buschmann MD. Drilling and microfracture lead to different bone structure and necrosis during bone-marrow stimulation for cartilage repair. J Orthop Res. 2009 Nov;27(11):1432-8. Chen H, Hoemann CD, Sun J, Chevrier A, McKee MD, Shive MS, Hurtig M, Buschmann MD. Depth of subchondral perforation influences the outcome of bone marrow stimulation cartilage repair. J Orthop Res. 2011 Aug;29(8):1178-84. Fortier LA, Cole BJ, McIlwraith CW. Science and animal models of marrow stimulation for cartilage repair. J Knee Surg. 2012 Mar;25(1):3-8. Eldracher M. et al. Small Subchondral Drill Holes improve Marrow Stimulation of Articular Cartilage Defects. Am J Sports Med. 2014 Nov;42(11):2741-50. |
||||||||||||||||||||||||||||||||
119 | Y | 2000128 | 5500-1020 Nano FX Guide 15 Degree (Reusable) - 1 piece | NANOFRACTURING WITH NANOFX® |
Microfracturing is increasingly criticized as a treatment option for focal cartilage defects and, according to professional societies and cartilage experts, should only be used in exceptional cases. Nanofracturing offers an effective alternative for the treatment of chondral and osteochondral defects. NanoFx® is a bone marrow stimulation system that provides a standardized procedure for nanofracturing. Deep perforation of the subchondral plate and sub-articular cancellous bone creates direct access channels into the medullary canal through which mesenchymal stem cells (MSCs) can infiltrate into the cartilage defect. This bleeding in with accompanying recruitment of MSC is a prerequisite for cartilage regeneration. Due to the 9 mm deep perforation using NanoFx®, high yields of MSC can be achieved, promoting high-quality cartilage regeneration with a hyaline-like character. In addition, due to the 1 mm thin diameter, the subchondral plate and cancellous bone are spared, with the aim of promoting rapid healing and restoration of the subchondral bone. ADVANTAGES OF NANOFRACTURING
NANOFX® AND HYALOFAST® CONVINCING ONE-STEP CARTILAGE REGENERATION WITH THE COMBINATION OF NANOFX® AND HYALOFAST® NanoFx® and Hyalofast® offer a modern therapeutic concept for the treatment of chondral and osteochondral defects. Nanofracturing is a standardized procedure for the recruitment of mesenchymal stem cells (MSC) from the medullary canal. Matrix augmented cartilage regeneration with Hyalofast® promotes MSC differentiation to support chondrogenesis through the biological activity of hyaluronic acid. Thus, NanoFx® and Hyalofast® complement each other to form an optimal therapeutic concept for the treatment of cartilage defects.
FAST AND EASY APPLICATION The NanoFx® Guide can be inserted into the defect arthroscopically or minimally invasively and requires no specific incisions. With the sterile disposable needle, a sharp instrument is always at hand to perforate the subchondral plate. NanoFx® is easy to put together and therefore quickly ready for use. Compared to microfracturing, the force of the hammer blow is optimally transferred to the 1 mm thin tip of the needle, so that even light blows are sufficient. Due to the integrated depth limitation, the needle is always inserted into the cancellous bone to a depth of 9 mm in a controlled manner. Application of NanoFx®: Step 1: Insert the PleuriStik needle, tip down, through the opening of the Thumb Tab and through the proximal opening of the NanoFX® Guide without the needle being visible at the distal tip of the guide. Step 2: Place the tip of the NanoFx® Guide 2-3 mm in front of the intact cartilage wall away into the defect. Place the tip of the NanoFX® Guide only lightly on the subchondral plate. Step 3: Lightly tap the exposed proximal tip of the needle several times with a hammer to insert the needle into the defect to the depth limit of 9mm. Step 4: To retract the needle one-handed, press down on the thumb tab with your thumb. This will lever the PleuriStik needle out of the NanoFx® Guide. To perform additional perforations, reposition the guide and repeat steps 2-4. The NanoFx® Guide is reusable and must be cleaned and sterilized after use. NANOFX® SHORT AND COMPACT Product: NanoFx® - Instrument for bone marrow stimulation Article: NanoFx® Guide, PleuriStik Nitinol needle, Thumb Tab Approval: medical device with CE mark Sterilization: gamma sterilized Storage: store in a dry place DEVELOPMENT OF NANOFRACTURING Bone marrow stimulation to recruit progenitor cells into the cartilage defect is a well-established therapeutic option in cartilage regeneration. Since the late 1980s, microfracturing emerged as the primary treatment choice because of its low cost, relatively low morbidity, and encouraging results as an initial procedure for cartilage defects, especially in young and active patients (1-3). Renewed interest in the effects on subchondral bone shed new light on the limitations of microfracturing: shallow channels, wall compression, and an increase in trabecular wall thickness and density were observed computed tomographically and histologically (4-6). Chen et al. reported that deeper subchondral bone marrow stimulation resulted in improved cartilage defect filling, more type 2 collagen, and less type 1 collagen than shallow bone marrow access (5). A study by Eldracher et al (7), showed that 1 mm thin holes had improved histo- gy, cancellous bone restoration, and immunoreactivity to type 2 collagen compared to 1.8 mm wide holes. The nonstandard depth, diameter, and perforation density of microfracturing led to the development of a new method to perforate the subchondral plate (nanofracturing), which has a standardized depth of 9 mm and a diameter of 1 mm. LITERATURE Kreuz PC, Steinwachs MR, Erggelet C, Krause SJ, Konrad G, Uhl M, Südkamp N. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage. 2006 Nov;14(11):1119-25. Mithoefer K, Williams RJ 3rd, Warren RF, Potter HG, Spock CR, Jones EC, Wickiewicz TL, Marx RG. The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg Am. 2005 Sep;87(9):1911-20. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthroscopy. 2003 May-Jun;19(5):477-84. Chen H, Sun J, Hoemann CD, Lascau-Coman V, Ouyang W, McKee MD, Shive MS, Buschmann MD. Drilling and microfracture lead to different bone structure and necrosis during bone-marrow stimulation for cartilage repair. J Orthop Res. 2009 Nov;27(11):1432-8. Chen H, Hoemann CD, Sun J, Chevrier A, McKee MD, Shive MS, Hurtig M, Buschmann MD. Depth of subchondral perforation influences the outcome of bone marrow stimulation cartilage repair. J Orthop Res. 2011 Aug;29(8):1178-84. Fortier LA, Cole BJ, McIlwraith CW. Science and animal models of marrow stimulation for cartilage repair. J Knee Surg. 2012 Mar;25(1):3-8. Eldracher M. et al. Small Subchondral Drill Holes improve Marrow Stimulation of Articular Cartilage Defects. Am J Sports Med. 2014 Nov;42(11):2741-50. |
||||||||||||||||||||||||||||||||
120 | Y | 2000129 | 5500-4010 Nano FX Guide A Curve (Reusable) - 1 piece | NANOFRACTURING WITH NANOFX® |
Microfracturing is increasingly criticized as a treatment option for focal cartilage defects and, according to professional societies and cartilage experts, should only be used in exceptional cases. Nanofracturing offers an effective alternative for the treatment of chondral and osteochondral defects. NanoFx® is a bone marrow stimulation system that provides a standardized procedure for nanofracturing. Deep perforation of the subchondral plate and sub-articular cancellous bone creates direct access channels into the medullary canal through which mesenchymal stem cells (MSCs) can infiltrate into the cartilage defect. This bleeding in with accompanying recruitment of MSC is a prerequisite for cartilage regeneration. Due to the 9 mm deep perforation using NanoFx®, high yields of MSC can be achieved, promoting high-quality cartilage regeneration with a hyaline-like character. In addition, due to the 1 mm thin diameter, the subchondral plate and cancellous bone are spared, with the aim of promoting rapid healing and restoration of the subchondral bone. ADVANTAGES OF NANOFRACTURING
NANOFX® AND HYALOFAST® CONVINCING ONE-STEP CARTILAGE REGENERATION WITH THE COMBINATION OF NANOFX® AND HYALOFAST® NanoFx® and Hyalofast® offer a modern therapeutic concept for the treatment of chondral and osteochondral defects. Nanofracturing is a standardized procedure for the recruitment of mesenchymal stem cells (MSC) from the medullary canal. Matrix augmented cartilage regeneration with Hyalofast® promotes MSC differentiation to support chondrogenesis through the biological activity of hyaluronic acid. Thus, NanoFx® and Hyalofast® complement each other to form an optimal therapeutic concept for the treatment of cartilage defects.
FAST AND EASY APPLICATION The NanoFx® Guide can be inserted into the defect arthroscopically or minimally invasively and requires no specific incisions. With the sterile disposable needle, a sharp instrument is always at hand to perforate the subchondral plate. NanoFx® is easy to put together and therefore quickly ready for use. Compared to microfracturing, the force of the hammer blow is optimally transferred to the 1 mm thin tip of the needle, so that even light blows are sufficient. Due to the integrated depth limitation, the needle is always inserted into the cancellous bone to a depth of 9 mm in a controlled manner. Application of NanoFx®: Step 1: Insert the PleuriStik needle, tip down, through the opening of the Thumb Tab and through the proximal opening of the NanoFX® Guide without the needle being visible at the distal tip of the guide. Step 2: Place the tip of the NanoFx® Guide 2-3 mm in front of the intact cartilage wall away into the defect. Place the tip of the NanoFX® Guide only lightly on the subchondral plate. Step 3: Lightly tap the exposed proximal tip of the needle several times with a hammer to insert the needle into the defect to the depth limit of 9mm. Step 4: To retract the needle one-handed, press down on the thumb tab with your thumb. This will lever the PleuriStik needle out of the NanoFx® Guide. To perform additional perforations, reposition the guide and repeat steps 2-4. The NanoFx® Guide is reusable and must be cleaned and sterilized after use. NANOFX® SHORT AND COMPACT Product: NanoFx® - Instrument for bone marrow stimulation Article: NanoFx® Guide, PleuriStik Nitinol needle, Thumb Tab Approval: medical device with CE mark Sterilization: gamma sterilized Storage: store in a dry place DEVELOPMENT OF NANOFRACTURING Bone marrow stimulation to recruit progenitor cells into the cartilage defect is a well-established therapeutic option in cartilage regeneration. Since the late 1980s, microfracturing emerged as the primary treatment choice because of its low cost, relatively low morbidity, and encouraging results as an initial procedure for cartilage defects, especially in young and active patients (1-3). Renewed interest in the effects on subchondral bone shed new light on the limitations of microfracturing: shallow channels, wall compression, and an increase in trabecular wall thickness and density were observed computed tomographically and histologically (4-6). Chen et al. reported that deeper subchondral bone marrow stimulation resulted in improved cartilage defect filling, more type 2 collagen, and less type 1 collagen than shallow bone marrow access (5). A study by Eldracher et al (7), showed that 1 mm thin holes had improved histo- gy, cancellous bone restoration, and immunoreactivity to type 2 collagen compared to 1.8 mm wide holes. The nonstandard depth, diameter, and perforation density of microfracturing led to the development of a new method to perforate the subchondral plate (nanofracturing), which has a standardized depth of 9 mm and a diameter of 1 mm. LITERATURE Kreuz PC, Steinwachs MR, Erggelet C, Krause SJ, Konrad G, Uhl M, Südkamp N. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage. 2006 Nov;14(11):1119-25. Mithoefer K, Williams RJ 3rd, Warren RF, Potter HG, Spock CR, Jones EC, Wickiewicz TL, Marx RG. The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg Am. 2005 Sep;87(9):1911-20. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthroscopy. 2003 May-Jun;19(5):477-84. Chen H, Sun J, Hoemann CD, Lascau-Coman V, Ouyang W, McKee MD, Shive MS, Buschmann MD. Drilling and microfracture lead to different bone structure and necrosis during bone-marrow stimulation for cartilage repair. J Orthop Res. 2009 Nov;27(11):1432-8. Chen H, Hoemann CD, Sun J, Chevrier A, McKee MD, Shive MS, Hurtig M, Buschmann MD. Depth of subchondral perforation influences the outcome of bone marrow stimulation cartilage repair. J Orthop Res. 2011 Aug;29(8):1178-84. Fortier LA, Cole BJ, McIlwraith CW. Science and animal models of marrow stimulation for cartilage repair. J Knee Surg. 2012 Mar;25(1):3-8. Eldracher M. et al. Small Subchondral Drill Holes improve Marrow Stimulation of Articular Cartilage Defects. Am J Sports Med. 2014 Nov;42(11):2741-50. |
||||||||||||||||||||||||||||||||
121 | Y | 2000127 | PCL COVID-19 Ag Gold Saliva Test - 5 pieces |
The PCL Spit Rapid Spit Test is an in vitro diagnostic medical device based on a rapid immunochromatographic assay (ICA) procedure and is designed for the qualitative detection of SARS-CoV-2 antigens in human saliva specimens. Available in the following packaging units: 1 pc. Pack, 5 pcs. Pack and 50 pcs. Pack Specimen Collection
|
|||||||||||||||||||||||||||||||||
123 | Y | HC001 | Monovisc 4 ml | Treat osteoarthritis efficiently |
Very high hyaluronic acid active ingredient content in only one injection KEYFACTS Very high active ingredient content
Patented crosslinking process
Outstanding efficacy and safety record
Maximum safety
Active ingredient content VERY HIGH ACTIVE INGREDIENT CONTENT AND CROSS-LINKING FOR LESS PAIN
MONOVISC® - SHORT AND COMPACT
|
||||||||||||||||||||||||||||||||
124 | Y | HC002 | Cingal 4 ml | Immediate and long-lasting pain relief for osteoarthritis |
The first combination preparation of hyaluronic acid and cortisone KEYFACTS 2 IN 1 - COMBINATION PREPARATION
1+ QUALITY
A PLUS FOR PATIENTS
Efficacy FAST AND LONG-LASTING EFFICACY
CINGAL® - SHORT AND COMPACT
|
||||||||||||||||||||||||||||||||
125 | Y | HC003 | Orthovisc Mini 1 ml | Proven osteoarthritis therapy with optimal molecular weight |
Especially for small joints - synovial joints. Orthovisc® mini is a highly pure hyaluronic acid preparation that improves joint function in osteoarthritis, contributes to long-lasting pain relief, and halts the progressive degeneration process in cartilage. KEYFACTS EFFECTIVE
SAFE
PATIENT-FRIENDLY
PROVEN EFFICACY WITH FDA APPROVAL ORTHOVISC® mini is a highly pure hyaluronic acid preparation that improves joint function in osteoarthritis, contributes to long-lasting pain relief and halts the progressive degeneration process in cartilage. Optimal molecular weight
Optimum viscosity
ORTHOVISC® mini – SHORT AND COMPACT
|
||||||||||||||||||||||||||||||||
126 | Y | HC004 | Orthovisc 2 ml | Proven osteoarthritis therapy with optimal molecular weight |
Orthovisc® is a highly pure hyaluronic acid preparation that improves joint function in osteoarthritis, contributes to long-lasting pain relief, and halts the progressive degeneration process in cartilage. KEYFACTS EFFECTIVE
SAFE
PATIENT-FRIENDLY
ORTHOVISC mini
PROVEN EFFICACY WITH FDA APPROVAL ORTHOVISC® is a highly pure hyaluronic acid preparation that improves joint function in osteoarthritis, contributes to long-lasting pain relief and halts the progressive degeneration process in cartilage. Optimal molecular weight
Optimum viscosity
ORTHOVISC® - SHORT AND COMPACT
|
||||||||||||||||||||||||||||||||
127 | Y | HC005 | Orthovisc - T 2 ml | Hyaluronic acid therapy for the treatment of tendopathies |
ORTHOVISC®-T is an injectable viscoelastic sodium hyaluronate solution for the treatment of chronic lateral epicondylopathy. ORTHOVISC®-T acts as a lubricant to help the tendon glide in the tendon sheath. This supports the healing process of the tendon. KEYFACTS PROVEN EFFICACY
PROVEN SAFETY
THE THERAPY OPTION FOR THE TREATMENT OF PAIN AND LIMITED MOBILITY ASSOCIATED WITH TENDON DISORDERS Orthovisc-T improves tendon biomechanics
ORTHOVISC®-T - SHORT AND COMPACT
|
||||||||||||||||||||||||||||||||
128 | Y | HC006 | Impact ACS |
Autologous Conditioned Serum for the preparation of an autologous conditioned serum. Application
Focus and goal of therapy
|
|||||||||||||||||||||||||||||||||
129 | Y | HC007 | Impact PRP |
Without anticoagulant for the preparation of lightly concentrated platelet-rich plasma. Application wPRP - Acute:
wPRP – Chronic
Concentration / Yield
|
|||||||||||||||||||||||||||||||||
130 | Y | HC008 | Impact APC |
Autologous Platelet Concentrate with anticoagulant for the preparation of highly concentrated platelet concentrate. Application
Concentration / Yield
|
|||||||||||||||||||||||||||||||||
131 | Y | HC009 | Impact Centrifuge | Platform for autologous cell therapies - One system - numerous therapy options |
The IMPACT system offers the user the possibility to produce different autologous blood products with only one platform. Autologous blood products use the body´s own regeneration mechanisms. After injection to the defect, they support the body in healing injured tissue in a purely natural way. IMPACT´s innovative technology allows variable concentrations of leukocytes and platelets. Content: Impact centrifuge, rolling container, Neolab rotator 90-27 degrees adjustable, Neolab turntable f. rotator KEYFACTS ÜBERLEGENES HANDLING
UNIQUE RESULTS
HIGH FLEXIBILITY
MAXIMUM SAFETY
Reliable technology for reproducible results With IMPACT, centrifugation and separation of the desired blood fractions takes place fully automatically in a closed system. The built-in optical sensor is adjustable in its sensitivity and separates reliably and accurately. The syring containing the patient´s blood is inserted and - after the program has run down - the desired autologous blood product is withdran "ready to use". Innovative and customizable production of autologous blood products - with just one system Three treatment sets are available. The selection is made depending on the respective therapy goal: IMPACT PRP – Platelet Rich Plasma IMPACT APC – Autologous Platelet Concentrate IMPACT ACS – Autologous Conditioned Serum |
auf anzeigen